Diagnostics

Are Handheld Ultrasound Imaging Devices a True Revolution in Diagnostic Imaging Domain?

  • by

Advancements in the field of disease diagnostics have led to development of point-of-care medical imaging devices; handheld ultrasound scanners have emerged as a novel solution to cater to unmet need in this domain. These handheld ultrasound imaging devices are the lightest portable ultrasound devices, which… Read More »Are Handheld Ultrasound Imaging Devices a True Revolution in Diagnostic Imaging Domain?

Healthcare investing sets a new record in Q3

  • by

Global healthcare funding set a new record in the third quarter, according to data from CBInsights. Healthcare companies raised a total of $21.8 billion across 1,539 deals.

Lessons learned from Verily’s Covid-19 testing efforts

  • by

Google’s sister company launched a program in California and other states to help route patients to nearby coronavirus testing. Dr. Vivian Lee, president of health platforms for Verily, shared lessons learned from that effort and Verily’s work with schools and businesses.

Cue Health gets $481M to expand production of rapid coronavirus test

  • by

San Diego-based diagnostics startup Cue Health won a $481 million from the Department of Health and Human Services and the Department of Defense to produce more coronavirus tests. The company received an emergency use authorization in June for its rapid molecular test.

Genentech Collaborates with Imbio to Develop Imaging Diagnostics for Lung Diseases

  • by

Shots: The agreement leverages Imbio’s technical, regulatory & commercial expertise to build medical imaging AI technology for use in research, clinical trials & clinical practice The focus of the agreement is to develop quantitative imaging diagnostics for lung diseases and to bring unique solutions for… Read More »Genentech Collaborates with Imbio to Develop Imaging Diagnostics for Lung Diseases

J.P. Morgan on the state of life sciences and strategies to fuel innovation [Sponsored]

  • by

In an interview, Peter Meath, J.P. Morgan’s co-head of Healthcare and Life Sciences, Middle Market Banking & Specialized Industries, says the Covid-19 pandemic has cast a bright light on the life sciences industry with startups raising venture funding at record levels as the virus has… Read More »J.P. Morgan on the state of life sciences and strategies to fuel innovation [Sponsored]

Why MedCity News should be your go-to advertising partner

  • by

MedCity News has the most engaged healthcare business audience in the industry. We can collaborate with you to develop customized content or provide a platform for your business to present sponsored thought leadership content highlighting from executives in healthcare and life sciences.

Founders’ Story: Truvian Sciences

  • by

In a Q&A, Truvian Sciences CEO Jeff Hawkins and Dena Marrinucci, founder and SVP Corporate Development and Business Operations talk about their point-of care blood testing technology.

Eli Lilly’s P-tau217 Blood Test Demonstrate High Accuracy in Diagnosis of Alzheimer’s Disease

  • by

Shots: The study involved 1402 patients across 3 cohorts: a) 81 patients in Arizona (34 with AD and 47 without), b) 699 in Sweden (301 with no cognitive impairment, 178 with mild cognitive impairment, 121 with AD dementia and 99 with other neurodegenerative diseases) and… Read More »Eli Lilly’s P-tau217 Blood Test Demonstrate High Accuracy in Diagnosis of Alzheimer’s Disease

Who won the MedCity INVEST Pitch Perfect competition?

  • by

Healthcare startups across health services, health IT, medical devices, biopharma and diagnostics tracks took part in the week-long competition at the conference July 20-24. Here are the winners for the five tracks.

Healthcare deals dip in 2020, but not as much as expected

  • by

Healthcare mergers decreased in the first half of 2020, but not to the extent expected as a result of the Covid-19 pandemic. Reports by Pricewaterhouse Coopers and Kaufman Hall showed a decline in mergers and acquisitions, but still reported sustained interest from buyers

A brief history of the future of genomics

  • by

Naysayers have been proven wrong multiple times over as companies across the biotech industry have advanced to deliver diagnostics and detection assays across a number of different cancer types enabling predictive testing, early diagnosis and objective results.